Table 1.

US FDA-approved cancer drugs targeting fusion genes. Only three out of 35 drugs approved for BCR-ABL1 fusion are shown (Data collected from https://nctr-crs.fda.gov/fdalabel/ui/search).

Cancers	Targeted kinase fusion partners	Drug	Approval, year	Reference
Ph+ CMLa	BCR-ABL1	Imatinib	2001	Amarante-Mendes et al.75, Milojkovic and Apperle76
Ph+ CMLa	BCR-ABL1	Nilotinib	2010	Amarante-Mendes et al.75, Radich et al.77
NSCLC ALK or ROS1 positiveb, ALCL ALK positivec	ALK, ROS1, MET	Crizotinib	2011	Shaw et al.,78 Solomon et al.79
NSCLC ALK positived	ALK, ROS1	Ceritinib	2014	Facchinetti et al.80
NSCLC ALK positived	ALK, ROS1, EGFR	Brigatinib	2017	Descourt et al.81
NSCLC ALK positive	ALK	Alectinib	2017	Wang et al.82
Solid tumors with NTRK gene fusions	NTRK1-3	Larotrectinib	2018	Rudzinski et al.83
NSCLC ROS1 positivee, solid tumors with NTRK fusions	NTRK, ROS1, ALK	Entrectinib	2019	Dziadziuszko et al.,84 Doebele et al.85
Urothelial cancer with FGFR3 fusion	FGFR3	Erdafitinib	2019	Zengin et al.86
Cholangiocarcinoma with FGFR2 fusion	FGFR1-3	Pemigatinib	2020	Abou-Alfa et al.87
RET-positive NSCLC, thyroid cancerf	RET	Pralsetinib	2020	Gainor et al.88
RET-positive NSCLC, thyroid cancerf	RET, VEGFR1, VEGFR3	Selpercatinib	2020	Subbiah et al.89
NSCLC ALK positive	ALK	Lorlatinib	2021	Sehgal et al.,90 Descourt et al.81
Cholangiocarcinoma with FGFR2 fusion	FGFR2	Infigratinib	2021	Javle et al.91
Ph+ CMLa	BCR-ABL1	Asciminib	2021	Yeung et al.92

^aPh⁺ CML – chronic myeloid leukemias with Philadelphia chromosome.

^bNSCLC ALK or ROS1 positive – non-small-cell lung cancers harboring translocations of ALK or ROS1 genes.

^cALCL ALK positive – anaplastic large-cell lymphoma, systemic ALK-Positive.

^dNSCLC ALK positive – non-small-cell lung cancers with translocation of ALK gene.

^eNSCLC ROS1 positive – non-small-cell lung cancers with translocation of ROS1 gene.

^fRET-positive NSCLC – non-small-cell lung cancers with translocation of RET gene.